Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection

Anchorperson: D. Capodanno

Spokesperson: M. Gilard

Summary

This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.

Learning Objectives

To evaluate antithrombotic strategies after TAVI in patients with and without atrial fibrillation, considering thrombotic and bleeding risk
To analyse the clinical presentation and management of valve thrombosis post-TAVI
To apply guideline-based decision-making to individualise therapy across diverse post-TAVI scenarios using real patient cases

Presentations available when logged in:

Welcome and session objectives
A patient in sinus rhythm undergoing TAVI
The evidence and guidance in a nutshell
A patient in atrial fibrillation undergoing TAVI
The evidence and guidance in a nutshell
A patient with clinical valve thrombosis
The evidence and guidance in a nutshell
Session evaluation and key learnings

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection

Learning Objectives

Log in or create account for free